Abraxus Pharm

Abraxis BioScience was a fully integrated biotechnology company dedicated to delivering progressive therapeutics and leveraging its proprietary nanoparticle albumin-bound (nab) technology platform. The company's flagship product, Abraxane, revolutionized the delivery of chemotherapy by using albumin to transport paclitaxel directly to tumors, eliminating the need for toxic solvents. Abraxis focused on developing a pipeline of products for the treatment of cancer and other critical illnesses. In 2010, the company was acquired by Celgene Corporation in a multi-billion dollar deal, primarily to secure the global rights to Abraxane and the nab technology platform.